Is the NHS ready to exploit RWE for patients routinely excluded from clinical trials?

  •  “Immune Checkpoint Inhibitors (ICIs) were first approved for the treatment of aNSCLC in 2014, and since this time have seen rapid adoption in the marketplace. [This study] sought to describe the characteristics of patients with aNSCLC receiving ICIs in the real-world, as well as to examine treatment patterns and outcomes in the time since initial ICI approval”
  • “This analysis demonstrates that aNSCLC patients receiving ICI therapy in the real-world are older than what was reported in some clinical trials, though survival outcomes were similar. Further research to examine impact of covariates on outcomes is warranted.”

Click here to see the source article 

Reference

Sean Khozin, Jizu Zhi, Monika Jun, Li Chen, Wendy S. Rubinstein, Mark S. Walker, George Anthony Komatsoulis, Jeremy Roberts, Ryan Fukushima, Denise Lau, Brigham Hyde, Edward Stepanski, Robert S. Miller; U.S. Food and Drug Administration, Silver Spring, MD; Concerto HealthAI, Boston, MA; American Society of Clinical Oncology’s (ASCO) CancerLinQ, Alexandria, VA; ACORN Research LLC, Memphis, TN; Tempus, Chicago, IL J Clin Oncol 37, 2019 (suppl; abstr 9110)

 

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

 

Posted in Blogs.